Skip to main content

Advertisement

SpringerLink
Log in

Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the effects of latanoprost, bimatoprost, and travoprost eye drops and their preservatives on each corneal layer thickness in patients with primary open-angle glaucoma (POAG).

Methods

We retrospectively analyzed 79 eyes of 79 patients with POAG who were receiving prostaglandin therapy. Patients were divided into three subgroups according to monotherapy with latanoprost, bimatoprost, and travoprost during a mean of 43.14 ± 19.12 months follow-up period. In addition, the central corneal epithelial thickness (CET), central corneal stromal thickness (CST), and total central corneal thickness (CCT) were measured by anterior segment optical coherence tomography (AS-OCT) at baseline and every six months after treatment initiation at each visit between 9 and 12 o'clock in the morning. Furthermore, intraocular pressure (IOP) was measured with Goldmann applanation tonometry (GAT) after AS-OCT measurements at each visit.

Results

All three groups were not significantly different in age, gender, follow-up period, and mean intraocular pressure values (p > 0.05 for all). The reduction of CCT in the latanoprost, bimatoprost, and travoprost groups was 6.53 ± 3.17, 18.59 ± 8.42, and 10.1 ± 1.13 µm, respectively. The decrease in CST values was 4.65 ± 1.54, 15.84 ± 7.47, 9.69 ± 1.45 µm, and CET values were 1.88 ± 1.66, 2.75 ± 0.73, 0.41 ± 0.54 µm in all groups, respectively. A statistically significant thinning was observed in all corneal layers (p < 0.05) except the CST values in the latanoprost group and CET values in the travoprost group. However, no significant difference was found in the average reduction of CET, CST, and CCT values among the three groups (p > 0.05).

Conclusion

Topical treatment with latanoprost, bimatoprost, and travoprost affects each layer of the cornea separately according to the active and protective substances contained in these eye drops. On the other hand, the thinning effect on the corneal layers was similar in these three drugs because there was no significant difference between the three groups in the total amount of thinning of the corneal layers during the follow-up period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Van Buskirk EM, Cioffi GA (1992) Glaucomatous optic neuropathy. Am J Ophthalmol 113:447–452

    Article  PubMed  Google Scholar 

  2. Tham Y-C, Li X, Wong TY et al (2014) Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 121:2081–2090

    Article  PubMed  Google Scholar 

  3. Kwon YH, Fingert JH, Kuehn MH et al (2009) Primary open-angle glaucoma. N Engl J Med 360:1113–1124

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Cavdarli C, Yarangumeli A, Aki H, Kural G (2015) Short-term effects of latanoprost on intraocular pressure, central corneal thickness and anterior chamber depth in open-angle glaucoma. Int Eye Sci 15:2040–2044

    CAS  Google Scholar 

  5. Meda R, Wang Q, Paoloni D, Harasymowycz P et al (2017) The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open-angle glaucoma. Br J Ophthalmol 101:120–125

    Article  PubMed  Google Scholar 

  6. Goldmann H, Schmidt T (1957) About applanation tonometry. Ophthalmologica 134:221–242

    Article  CAS  PubMed  Google Scholar 

  7. Gordon MO, Beiser JA, Brandt JD et al (2002) The Ocular Hypertension Treatment Study: Baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol 120:714–720

    Article  PubMed  Google Scholar 

  8. Schlote T, Tzamalis A, Kynigopoulos M (2009) Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients. J Ocul Pharmacol Ther 25:459–462

    Article  CAS  PubMed  Google Scholar 

  9. Peter GK, Najam AS (2019) Discovery, characterization and clinical utility of prostaglandin agonists for the treatment of glaucoma. Br J Pharmacol 176:1051–1058

    Article  Google Scholar 

  10. Lim KS, Nau CB, O’Byrne MM et al (2008) Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study Ophthalmol 115:790–795

    Google Scholar 

  11. Weinreb RN, Lindsey JD (2002) Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest Ophthalmol Vis Sci 43:716–722

    PubMed  Google Scholar 

  12. Schlötzer-Schrehardt U, Zenkel M, Nüsing RM (2002) Expression and localisation of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest Ophthalmol Vis Sci 43:1475–1487

    PubMed  Google Scholar 

  13. Wu KY, Wang HZ, Hong SJ (2005) Effect of latanoprost on cultured porcine stromal cells. Curr Eye Res 30:871–879

    Article  CAS  PubMed  Google Scholar 

  14. Stefan C, Dumitrica DM, Tebeanu E et al (2007) Prostaglandin analogues and central corneal thickness. Oftalmologia 51:95–99

    CAS  PubMed  Google Scholar 

  15. Harasymowycz PJ, Papamatheakis DG, Ennis M et al (2007) Travoprost central corneal thickness study group Relationship between travoprost and central corneal thickness in ocular hypertension and open-angle glaucoma. Cornea 26:34–41

    Article  PubMed  Google Scholar 

  16. Brandt JD, Gordon MO, Beiser JA et al (2008) Changes in central corneal thickness over time: The ocular hypertension treatment study. Ophthalmology 115:1550–1556

    Article  PubMed  Google Scholar 

  17. Sen E, Nalcacioglu P, Yazici A et al (2008) Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J Glaucoma 17:398–402

    Article  PubMed  Google Scholar 

  18. Hatanaka M, Vessani RM, Elias IR et al (2009) The effect of prostaglandin analogs and prostamide on central corneal thickness. J Ocul Pharmacol Ther 25:51–53

    Article  CAS  PubMed  Google Scholar 

  19. Bafa M, Georgopoulos G, Mihas C et al (2011) The effect of prostaglandin analogues on central corneal thickness of patients with chronic open-angle glaucoma: A 2-year study on 129 eyes. Acta Ophthalmol 89:448–451

    Article  CAS  PubMed  Google Scholar 

  20. Yee RW (2007) The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr Opin Ophthalmol 18:134–139

    Article  PubMed  Google Scholar 

  21. Muz OE, Dagdelen K, Pirdal T et al (2021) Comparison of BAK-preserved latanoprost and polyquad-preserved travoprost on ocular surface parameters in patients with glaucoma and ocular hypertension. Int Ophthalmol 41:3825–3835

    Article  PubMed  Google Scholar 

  22. Nam SM, Im CY, Lee HK et al (2010) Accuracy of RTVue optical coherence tomography, Pentacam, and ultrasonic pachymetry for the measurement of central corneal thickness. Ophthalmology 117:2096–2103

    Article  PubMed  Google Scholar 

  23. BMJ Publishing Group Ltd BMA House, Square T, London, 9jr W. 2017 European Glaucoma Society Terminology and Guidelines for Glaucoma 4th Edition - Chapter 2: classification and terminology, Br J Ophthalmol, 101:73–127

  24. Fogagnolo P, Capizzi F, Orzalesi N et al (2010) Can mean central corneal thickness and its 24-hour fluctuation influence fluctuation of intraocular pressure? J Glaucoma 19:418–423

    Article  PubMed  Google Scholar 

  25. McCafferty S, Lim G, Duncan W et al (2016) Goldmann tonometer prism with an optimized error correcting applanation surface. Transl Vis Sci Technol 5:4

    Article  PubMed  PubMed Central  Google Scholar 

  26. Viswanathan D, Goldberg I, Graham SL et al (2013) Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clin Experiment Ophthalmol 41:348–354

    Article  PubMed  Google Scholar 

  27. Schrems WA, Schrems-Hoesl LM, Mardin CY et al (2016) The effect of long-term antiglaucomatous drug administration on central corneal thickness. J Glaucoma 25:274–280

    Article  PubMed  Google Scholar 

  28. Ocklind A (1998) Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67:179–191

    Article  CAS  PubMed  Google Scholar 

  29. Weinreb RN, Kashiwagi K, Kashiwagi F et al (1997) Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 38:2772–2780

    CAS  PubMed  Google Scholar 

  30. You JY, Cho BJ (2013) Effect of latanoprost on central corneal thickness in unilateral normal-tension glaucoma. J Ocul Pharmacol Ther 29:335–338

    Article  CAS  PubMed  Google Scholar 

  31. Jang M, Kang KE, Cho BJ (2020) Effect of prostaglandin analogues on central corneal thickness: 3-year follow-up results. Korean J Ophthalmol 34:347–352

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Zhong Y, Shen X, Yu J et al (2011) The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. Cornea 30:861–864

    Article  PubMed  Google Scholar 

  33. Liu Y, Yanai R, Lu Y et al (2006) Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fibroblasts. J Glaucoma 15:255–259

    Article  PubMed  Google Scholar 

  34. Oh DJ, Martin JL, Williams AJ et al (2006) Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest Ophthalmol Vis Sci 47:3887–3895

    Article  PubMed  Google Scholar 

  35. Zhou L, Zhan W, Wei X (2022) Clinical pharmacology and pharmacogenetics of prostaglandin analogues in glaucoma. Front Pharmacol 13:1015338

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Kunapuli P, Lawson JA, Rokach J et al (1997) Functional characterization of the ocular prostaglandin f2alpha (PGF2alpha) receptor Activation by the isoprostane 12-iso-PGF2alpha. J Biol Chem 272:27147–27154

    Article  CAS  PubMed  Google Scholar 

  37. Ehlers N, Bramsen T, Sperling S (1975) Applanation tonometry and central corneal thickness. Acta Ophthalmol 53:34–43

    Article  CAS  Google Scholar 

  38. Sen E, Inanc M, Elgin U (2019) The effect of topical latanoprost on corneal clarity; 1-year prospective study. Cutan Ocul Toxicol 38:253–257

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

The authors declare no financial support.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey

    Numan Eraslan & Osman Celikay

Authors
  1. Numan Eraslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Osman Celikay
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NE and OC took part in all steps of the manuscript together.

Corresponding author

Correspondence to Numan Eraslan.

Ethics declarations

Conflict of interest

All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. The authors indicate no financial support or financial conflict of interest. The authors have indicated they have no financial relationships with any company and no external funding.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Eraslan, N., Celikay, O. Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography. Int Ophthalmol 43, 3175–3184 (2023). https://doi.org/10.1007/s10792-023-02717-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-023-02717-y

Keywords

Search

Navigation